Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Avadel Pharmaceuticals plc - Ordinary Share (NQ:AVDL)

18.73 +0.04 (+0.19%)
Streaming Delayed Price Updated: 11:08 AM EST, Nov 10, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Avadel Pharmaceuticals plc - Ordinary Share

< Previous 1 2 3 4 5 6 Next >
Avadel Pharmaceuticals (NASDAQ:AVDL) Meets Minervini Trend Template with High-Growth Momentum
Avadel Pharmaceuticals (AVDL) meets the Mark Minervini Trend Template with a strong technical uptrend and accelerating earnings and sales growth momentum. 
Via Chartmill
Deal Dispatch: From Four Roses Bourbon To Quantum Stakes, Here Are This Week's Sector Shake Ups
Four Roses, Six Flags, and Trump's potential Quantum investments: This week's deal activity involves big bets across various sectors. 
Via Benzinga
Topics Government
HALPER SADEH LLC ENCOURAGES FSFG, AVDL, MBCN SHAREHOLDERS TO CONTACT THE FIRM TO DISCUSS THEIR RIGHTS
Shareholders should contact the firm immediately as there may be limited time to enforce your rights. 
From Halper Sadeh LLC
Via GlobeNewswire
Earnings Scheduled For August 7, 2025
 
Via Benzinga
Earnings Scheduled For May 7, 2025
 
Via Benzinga
Earnings Outlook For Avadel Pharmaceuticals
 
Via Benzinga
Earnings Scheduled For November 12, 2024
 
Via Benzinga
Tesla To Rally More Than 16%? Here Are 10 Top Analyst Forecasts For Thursday
 
Via Benzinga
This Winnebago Industries Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Thursday
 
Via Benzinga
Avadel Pharmaceuticals Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Avadel Pharmaceuticals plc - AVDL
From Kahn Swick & Foti, LLC
Via Business Wire
Alkermes Strikes $2.1 Billion Avadel Deal, Gains Access To Narcolepsy Drug Lumryz
Alkermes agrees to acquire Avadel for $2.1 billion, adding the successful Lumryz drug and accelerating entry into sleep medicine. Jazz litigation settled. 
Via Benzinga
Beyond The Numbers: 5 Analysts Discuss Avadel Pharmaceuticals Stock
 
Via Benzinga
Avadel Pharmaceuticals Soars as Alkermes Announces $2.1 Billion Acquisition
DUBLIN, IRELAND – October 22, 2025 – Avadel Pharmaceuticals (NASDAQ: AVDL) shareholders are celebrating today as Alkermes plc (NASDAQ: ALKS) announced a definitive agreement to acquire the company for... 
Via MarketMinute
Topics Intellectual Property
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Avadel Pharmaceuticals plc (Nasdaq – AVDL), Middlefield Banc Corp. (Nasdaq – MBCN), Heidrick & Struggles International, Inc. (Nasdaq - HSII), Comerica Incorporated
From Brodsky & Smith LLC
Via GlobeNewswire
Avadel Jumps On $2.1 Billion Takeover Deal. But Buyer, Alkermes, Dives.
The companies are both working in the sleep space, focusing on excessive daytime sleepiness. 
Via Investor's Business Daily
Avadel Stock Rises After Acquisition Offer By Alkermes
Alkermes will buy Avadel for up to $20 per share. 
Via Stocktwits
AVDL Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Avadel Pharmaceuticals plc Is Fair to Shareholders
From Halper Sadeh LLC
Via Business Wire
What 4 Analyst Ratings Have To Say About Avadel Pharmaceuticals
 
Via Benzinga
This Unisys Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday
 
Via Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
 
Via Benzinga
Avadel (AVDL) Q2 Revenue Jumps 64%
Via The Motley Fool
Topics Intellectual Property
Avadel Pharmaceuticals (NASDAQ:AVDL) Surges 6.3% in Pre-Market as Q2 Earnings Crush Estimates on Strong LUMRYZ Performance
Avadel Pharmaceuticals (AVDL) beats Q2 2025 estimates with $68.1M revenue and $0.10 EPS, driven by strong LUMRYZ™ adoption. Stock surges 6.3% pre-market. 
Via Chartmill
Avadel Shareholder Seeks Board Shakeup, Citing Millions Lost On Lumryz
ASL demands Avadel replace its board over failures in marketing Lumryz and urging a review of strategic options 
Via Benzinga
Avadel Pharmaceuticals Under Fire? Investor Reportedly Demands Board Ouster, Sale Talks, $1B In Damages
ASL Strategic Value Fund plans to vote its $15 million stake against all Avadel board nominees at the July meeting and is pushing for contingent-value rights tied to potential legal payouts, according... 
Via Stocktwits
Topics ETFs Intellectual Property
Earnings Scheduled For March 3, 2025
 
Via Benzinga
3 Stocks With Robust Growth Outlooks Insiders Are Buying
Insiders are buying these three stocks. The underlying companies have robust growth outlooks and are on track to deliver in 2025. 
Via MarketBeat
There May Still Be Time to Get in on These 3 Trending Biotechs
Biotech firms as a group declined slightly in the last year amid a tough external environment, but these three companies could grow in 2025. 
Via MarketBeat
Topics ETFs Economy
Avadel Pharmaceuticals Misses Earnings Estimates But Posts 150% Sales Increase From Narcolepsy Drug LUMRYZ
Avadel Pharmaceuticals missed the fourth quarter sales estimate by 5.12%. Still, the sales of its narcolepsy drug, LUMRYZ rose by 150% YoY. 
Via Benzinga
C-Suite Buy of the Week: Unusual Insider Trading Trends as 2025 Approaches
 
Via Benzinga
Why Carvana Shares Are Trading Higher By Around 20%; Here Are 20 Stocks Moving Premarket
 
Via Benzinga
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.